Asparagus Capsule Consumption
Conditions
Brief summary
Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.
Detailed description
The study design was cross-sectional. Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. Analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.
Interventions
OTHERPlacebo capsule
Placebo capsule is categorized as other.
DIETARY_SUPPLEMENTAsparagus capsule
Asparagus capsule is categorized as dietary supplement.
Sponsors
Burapha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Participants were randomly divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups.
Eligibility
Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* Man or woman, aged between 18 to 59 years * Body mass index more than 23 (Asian criteria) * No history of hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer * No regular intake of dietary supplements, i.e., vitamins, antioxidants * No regular smokers or alcohol drinkers (\>2 times per week) * Not sportman or regular exerciser (\>2 times per week or \>150 min per week) * No food allergy, especially shoot
Exclusion criteria
\- Current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of blood protein carbonyl | Day 0 and end of 12 weeks | Concentration of blood protein carbonyl was measured in plasma in nmol/mg protein unit |
| Level of fat distribution | Day 0 and end of 12 weeks | Level of fat distribution was measured by ratio of waist (centimeter) to hip (centimeter) |
| Level of body fat | Day 0 and end of 12 weeks | Level of body fat was measured in percentage unit |
| Level of fat mass | Day 0 and end of 12 weeks | Level of fat mass was measured in kilogram unit |
| Concentration of blood glucose | Day 0 and end of 12 weeks | Concentration of blood glucose was measured in serum in mmol/L unit |
| Concentration of blood insulin | Day 0 and end of 12 weeks | Concentration of blood insulin was measured in serum in uU/mL (microunit/milliliter) unit |
| Concentrations of blood lipids | Day 0 and end of 12 weeks | Concentrations of total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured in serum in mg/dL unit |
| Concentration of blood malondialdehyde | Day 0 and end of 12 weeks | Concentration of blood malondialdehyde was measured in plasma in uM (micromolar) unit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of blood glucose from oral glucose tolerance test | At 0 minute before glucose consumption and at 30, 60, 90, 120 minutes after glucose consumption | Concentrations of blood glucose were measured before and after glucose consumption at 75 g/100 ml in mg/dL unit |
Countries
Thailand
Outcome results
None listed